Clinical Trials

MainTitle

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

This study is not yet open for participant recruitment. (see Contacts and Locations)

Verified May 2019 by Viriom

Sponsor
Viriom


Information provided by (Responsible Party)
Viriom
ClinicalTrials.gov Identifier
NCT03730311

First received: November 1, 2018
Last updated: May 16, 2019
Last Verified: May 2019
History of Changes
Purpose

Purpose

A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers. Each of 3 consequent groups (120 mg, 200 mg and 280mg) enrolls 6 active and 2 placebo subjects.

Condition Intervention Phase
HIV Infections

Drug : Elpida
Drug : placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase Ib, Single-Centre, Placebo-Controlled Randomised Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers

Further study details as provided by Viriom:

Primary Outcome Measures

  • Incidence of AEs and SAEs [ Time Frame: 36 days ]
    Incidence of AEs and SAEs
Secondary Outcome Measures:
  • elsulfavirine plasma concentration [ Time Frame: 36 days ]
    elsulfavirine plasma concentration
  • VM1500A plasma concentration [ Time Frame: 36 days ]
    active metabolite plasma concentration

Estimated Enrollment: 24
Study Start Date: May 2019
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: November 2019 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Elpida 120 mg once weekly
elsulfavirine 120mg or placebo orally once weekly for 4 weeks
Drug: Elpida

elsulfavirine, capsules

Other Name:
  • elsulfavirine
  • VM-1500
  • VM1500

Drug: placebo

placebo

Experimental: Elpida 200 mg once weekly
elsulfavirine 200mg or placebo orally once weekly for 4 weeks
Drug: Elpida

elsulfavirine, capsules

Other Name:
  • elsulfavirine
  • VM-1500
  • VM1500

Drug: placebo

placebo

Experimental: Elpida 280 mg once weekly
elsulfavirine 280mg or placebo orally once weekly for 4 weeks
Drug: Elpida

elsulfavirine, capsules

Other Name:
  • elsulfavirine
  • VM-1500
  • VM1500

Drug: placebo

placebo

Detailed Description:

The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 40 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  1. Healthy males or females aged between 18-40 years.
  2. Willing and able to complete all study procedures, visits and restrictions.
  3. Capable of giving written informed consent.
  4. Has been determined healthy by medical history, physical and vital signs examinations.
  5. Has normal results for the following screening tests: complete blood count (CBC), sodium, potassium, blood urea nitrogen (BUN), serum creatinine, fasting blood sugar (FBS), creatine kinase, total calcium, cholesterol, triglyceride, total protein, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and urinalysis.
  6. Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months [i.e., who have had menses within the preceding 24 months], or women who have not undergone surgical sterilization; specifically hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation), must have a negative serum or urine pregnancy test with a sensitivity of at least 40 mIU/mL at Screening and prior to drug dosing on Day 1.
  7. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant must agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 6 months after stopping study drug. Subjects must either be abstinent or a combination of TWO of the following methods MUST be used appropriately:
    • Condoms (male or female) with or without a spermicidal agent;
    • Diaphragm or cervical cap with spermicide;
    • Intrauterine device (IUD);
    • Hormonal-based contraception. Participants who are not of reproductive potential (women who have been postmenopausal for at least 24 consecutive months or have undergone hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation or men who have documented azoospermia) are eligible without requiring the use of contraceptives. Acceptable documentation of sterilization, menopause or male partner's azoospermia must be provided; serum follicle stimulating hormone (FSH) measurement can be used to document menopausal range.

  • Exclusion Criteria:
  • Hepatic or kidney disorders or any other disease or disorder which may in the opinion of the Investigator interfere with the results of the study or threaten the health of volunteers.
  • Clinically significant ECG abnormality according to ECG exam at Screening, subject's medical history or family history judged by the Investigator that the presence of, or an increased risk of cardiac abnormality.
  • Positive result for HIV, HCV or HBV at Screening.
  • Positive result for illicit drugs screen (opiates, amphetamines, cannabinoids or cocaine) or alcohol screen at Screening.
  • Active alcohol or and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Received the excluded medications (as shown in Appendix 3) within 14 days or 28 days prior to the first dose of study drug, or within the 5 half-lives of individual medication, whichever is longer.
  • Participated in a clinical study and received any investigational drug or vaccine or medical device within 90 days prior to the first dose of study drug.
  • Pregnancy or breast feeding, male partners of pregnant females. Inability to understand the Protocol or follow its instructions.

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT03730311

    Contacts

    Contact:   Tapanee Mahasanprasert +66(0) 2 412-1315 tapanee.mahasanprasert@aclires.com

    Locations

    Thailand
    Siriraj Hospital Not yet recruiting
    Bangkok, Thailand
    Contact: Somruedee Chatsiricharoenkul, Assoc. Prof., MD    +66 (0)2 412 1315

    Sponsors and Collaborators

    Viriom

    Investigators

    Principal Investigator: Somruedee Chatsiricharoenkul, Assoc. Prof., MD Siriraj Hospital Bangkok, Thailand
    More Information

    More Information


    Responsible Party: Viriom  
    ClinicalTrials.gov Identifier: NCT03730311   History of Changes  
    Other Study ID Numbers: HIV-VM1500-11  
    Study First Received: November 1, 2018  
    Last Updated: May 16, 2019  
    Individual Participant Data    
    Plan to Share IPD: Undecided  

    Studies a U.S. FDA-regulated Drug Product: No  
    Studies a U.S. FDA-regulated Device Product: No  
    Product Manufactured in and Exported from the U.S.: No  

    Additional relevant MeSH terms:
    HIV Infections

    ClinicalTrials.gov processed this data on July 19, 2019
    This information is provided by ClinicalTrials.gov.